Pharmacology and potential therapeutic uses of cannabis

British Journal of Anaesthesia

Volumn 81, Issue 1, 1998, Pages 77-84

  Hirst, Robert A ^a   Lambert, David G ^b   Nottcutt, William G ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c JAMES PAGET UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Anandamide; Cannabinoids; Cannabis; Pain, acute; Pain, chronic; Pharmacology, cannabinoids; Receptors, CB1 and CB2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; ANANDAMIDE; APPETITE STIMULANT; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; DEXANABINOL; DRONABINOL; LEVONANTRADOL; N [ENDO 1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL] 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL)PYRAZOLE 3 CARBOXAMIDE; NABILONE; RIMONABANT; UNCLASSIFIED DRUG;

AGNOSIA; ANALGESIC ACTIVITY; ANTIEMETIC ACTIVITY; ASTHMA; BACKACHE; CANCER PAIN; CHRONIC PAIN; DIABETIC NEUROPATHY; DRUG STRUCTURE; EPILEPSY; GLAUCOMA; HUMAN; INSOMNIA; MULTIPLE SCLEROSIS; MUSCLE RELAXATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; REVIEW; SOMNOLENCE; SPINAL CORD INJURY; TISSUE DISTRIBUTION; VOMITING;

EID: 0031822359     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/81.1.77     Document Type: Review

References (97)

1. Arreaza G, Devane WA, Omeir RL, Sajnani G, Kunz J, Cravatt BF, Deutsch DG. The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyses its formation via the condensation of arachidonic acid and ethanolamine. Neuroscience Letters 1997; 234: 59-62.
2. Bloom AS, Haavik CO, Strehlow D. Effects of A9-tetrahydro-cannabinol on ATPases in mouse brain subcellular fractions. Life Sciences 1978; 23: 1399-1404.
3. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M, Le Fur G, Casellas P. Activation of mitogen-activated protein-kinases by stimulation of the central cannabinoid receptor, CB1. Biochemical Journal 1995; 312: 637-641.
4. British Medical Association. Therapeutic uses of cannabis. UK: Harwood Academic Publishers, 1997.
5. 9tetrahydrocannabinol in the rat and mouse. Psychopharmacology 1972: 275-280.
6. Cadas H, Gaillet S, Beltramo M, Vanance L, Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. Journal of Neuroscience 1996; 16: 3934-3942.
7. Calignano A, La Rana G, Beltramo M, Makriyannis, Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor, AM404. European Journal of Pharmacology 1997; 337: R1-R2.
8. Carey MP, Burish TG, Brenner DE. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. Annals of Internal Medicine 1983; 99: 106-114.
9. 2+ current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. British Journal of Pharmacology 1992; 106: 231-232.
10. Childers SR, Pachco MA, Bennett BA, Edwards TA, Hampson RE, Mu J, Deadwyler SA. Cannabinoid receptors: G-protein-mediated signal transduction mechanisms. Biochemical Society Symposium 1993; 27-50.
11. Collins DR, Pertwee RG, Davies SN. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation. British Journal of Pharmacology 1995; 115: 869-870.
12. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. Journal of Pharmacology and Experimental Therapeutics 1996; 277: 586-594.
13. Compton DR, Rice KG, De Costa BR, Razdan RJ, Melvin LS, Johnson MR, Martin BR. Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities. Journal of Pharmacology and Experimental Therapeutics 1993; 265: 218-226.
14. Coutts AA, Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. British Journal of Pharmacology 1997; 121: 1557-1566.
15. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21: 175-185.
16. Deadwyler SA, Hampson RE, Mu J, Whyte A, Childers S. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP dependent process. Journal of Pharmacology and Experimental Therapeutics 1995; 273: 734-743.
17. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949.
18. Devane WA, Dysarz FA, Johnson R, Melvin LS, Hewlett AC. Determination and characterisation of a cannabinoid receptor in rat brain. Molecular Pharmacology 1988; 34: 605-613.
19. Dimarzo V, Depetrocellis L, BisognoT, Maurelli S. Pharmacology and physiology of the endogenous cannabimimetic mediator anandamide. Journal of Drug Development and Clinical Practice 1995; 7: 199-219
20. DiMarzo V, De Petrocellis L, Sepe N, Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochemical Journal 1996; 316: 977-984.
21. DiMarzo V, Fontana A, Cadas H, Schinelli S, Cinaino G, Schwartz J-C, Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372: 686-691.
22. Doblin R, Kleiman MAR. The medical use of marijuana: the case for clinical trials. Journal of Addictive Disorders 1995; 14: 5-14.
23. 2+-dependent release from rat brain of cannabinoid receptor binding activity. Journal of Neurochemistry 1992; 58: 780-782.
24. Facci L, Daltoso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast-cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proceedings of the National Academy of Sciences (USA) 1995; 92: 3376-3380.
25. 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. Journal of Pharmacology and Experimental Therapeutics 1994; 271: 1383-1390.
26. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, Hunden DC, Johnson DW, Chancy MO, Koppel GA, Brownstein M. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. Journal of Pharmacology and Experimental Therapeutics 1998; 284: 291-297.
27. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, Mitchell RL. Comparison of the pharmacology and signal transduction of the human CB1 and CB2 receptors. Molecular Pharmacology 1995; 48: 443-450.
28. Felder CC, Veluz JS, Williams HL, Brieley EM, Matsuda LA. Cannabinoid agonists stimulate both receptor- and non-receptor mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Molecular Pharmacology 1992; 42: 838-845.
29. Fowler CJ, Tiger G, Stenstrom A. Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. Journal of Pharmacology and Experimental Therapeutics 1997; 283: 729-734.
30. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. European Journal of Pharmacology 1993; 231: 313-314.
31. Galieque S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire, D, LeFur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry 1995; 232: 54-61.
32. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 1964; 86: 1646-1647.
33. Gerard CM, Mollereau G, Vassart H, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemical Journal 1991; 279: 129-134.
34. Glass M, Brotchie JM, Maneuf YP, Modulation of neurotransmission by cannabinoids in the basal ganglia. European Journal of Neurosciences 1997; 9: 199-203.
35. Glass M, Dragunow M, Faull RLM. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77: 299-318.
36. Griffin G, Fernando SR, Ross RA, McKay NG, Ashford MLJ, Shire D, Huffman JW, Yu S, Lainton JAH, Pertwee RG. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. European Journal of Pharmacology 1997; 339: 53-61.
37. Grinspoon L, Bakalar B. Marihuana - Forbidden Medicine. New Haven: Yale University Press, 1993.
38. Harris LS, Carchman RA, Martin BR. Evidence for the existence of specific cannabinoid binding sites. Life Sciences 1978; 22: 1131-1138.
39. Herkenham M, Groen BGS, Lynn AB, De Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Research 1991; 552: 301-310.
40. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, Rice KC. Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences (USA) 1990; 87: 1932-1936.
41. Hillard CJ, Campbell WB. Biochemistry and pharmacology of arachidonoylethanolamide, a putative endogenous cannabinoid. Journal of Lipid Research 1997; 38: 2383-2393.
42. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. Journal of Neurochemistry 1997; 69: 631-638.
43. Hillard CJ, Adron Harris R, Bloom AS. Effects of cannabis on the physical properties of brain membranes and phospholipid vesicles - flourescence studies. Journal of Pharmacology and Experimental Therapeutics 1985; 232: 579-588.
44. Hirst RA, Almond SA, Lambert DG. Characterisation of the rat cerebellar CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. Neuroscience Letters 1996; 220: 101-104.
45. Holister LE. Health aspects of cannabis. Pharmacological Review 1986; 38(1): 1-20.
46. Hewlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor -biochemical, anatomical and behavioral characterization. Trends in Neuroscience 1990; 13: 420-423.
47. Howlett AC. Inhibition of neuroblastoma adenylyl cyclase by cannabinoid and nantradol compounds. Life Sciences 1984; 35: 1803-1810.
48. Howlett AC, Qualey JM, Khachatrian LL. The involvement of Gi in the inhibition of adenylyl cyclase by cannabamimetic drugs. Molecular Pharmacology 1986; 29: 307-313.
49. Jansen EM, Haycock DA, Ward SJ, Seybold VS. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Research 1992; 575: 93-102.
50. Levitt M. Cannabinoids as antiemetics in cancer chemotherapy. In: Mechoulam R, ed. Cannabinoids as Therapeutic Agents. Boca Raton, Florida: CRC Press, 1986.
51. Lichtman AH, Martin BR. Spinal and supraspmal components of cannabinoid-induced antinociception. Journal of Pharmacology and Experimental Therapeutics 1991; 258: 517-523.
52. Lichtman AH, Martin BR. Cannabinoid-induced antinociception is mediated by a spinal alpha-2-noradrenergic mechanism. Brain Research 1991; 559: 309-314.
53. Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. Journal of Pharmacology and Experimental Therapeutics 1996; 276: 585-593.
54. Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacology and stereoselectivity of structurally novel Cannabinoids in mice. Journal of Pharmacology and Experimental Therapeutics 1988; 247: 1046-1051.
55. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proceedings of the National Academy of Sciences (USA) 1992; 89: 3825-3829.
56. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding and in-situ hybridization histochemistry. Neuroscience 1992; 48: 655-668.
57. Martin BR. Characterisation of the antinociceptive activity of intravenously administered delta-9-tetrahydrocannabinol in mice. In: Harvey DJ, ed. Marihuana '84. Oxford: IRL Press, 1985; 685-691.
58. Martin BR. Structural requirements for cannabinoid-induced antinociceptive activity in mice. Life Sciences 1985; 36: 1523-1530.
59. Martin WJ, Hohmann AG, Walker JM. Inhibition of noxious stimulus-evoked activity in the ventral postlateral nucleus of the thalamus by the cannabinoid WIN 55,212-2: correlation of electrophysiological effects with antinociceptive actions. Journal of Neuroscience 1996; 16: 6601-6611.
60. Matsuda LA, Lolait SJ, Brownstein MJ,Young AC, BonnerTL Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
61. Mechoulam R. The pharmacohistory of Cannabis saliva. In: Cannabinoids as therapeutic agents. Boca Raton, Florida: CRC Press, 1986.
62. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
63. The medical use of cannabis. Marihuana in science and medicine. Nahas GG. Ed. New York: Raven Press, 1984.
64. 8-tetrahydrocannabonol. Journal of Pharmacology and Experimental Therapeutics 1985; 234: 784-791.
65. Notcutt WG, Price M, Chapman G. Clinical experience with nabilone for chronic pain. Pharmaceutical Science 1997; 3: 551-555.
66. Noyes R, Brun KF, Avery DH, Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology and Therapeutics 1975; 18: 84-89.
67. Pertwee RG, Fernando SR, Nash JE, Courts AA. Further evidence for the presence of cannabinoid CB1 receptors in guinea pig small intestine. British Journal of Pharmacology 1996; 118: 2199-2205.
68. Pertwee RG. The central neuropharmacology of psychotrophic cannabinoids. Pharmacological Therapeutics 1988; 36: 189-194.
69. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology and Therapeutics 1997; 74: 129-180.
70. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shapard KV, Wardleigh R. Recent clinical experience with dronabinol. Pharmacology, Biochemistry and Behaviour 1991; 40: 695-700.
71. Poster DS, Penta JS, Bruno S, Macdonald JS. Delta-9-tetrahydrocannabinol in clinical oncology. Journal of the American Medical Association 1981; 245: 2047-2051.
72. 8-tetrahydrocannabinol analogues. Journal of Medical Chemistry 1997; 40: 3312-3318.
73. Rice W, Shannon JM, Burton F, Fiedeldey D. Expression of a brain-type cannabinoid receptor (CB1) in alveolar type II cells in the lung: regulation by hydrocortisone. European Journal of Pharmacology 1997; 327: 227-232.
74. Richardson JD, Aanonsen L, Hargreaves KM. SR141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. European Journal of Pharmacology 1997; 319: R3-R4.
75. Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Congy C, Soubrie P, Breliere J, Le-Fur G. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid antagonist. Life Sciences 1995; 56: 1941-1947.
76. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere J, Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 1994; 350: 240-244.
77. Rinaldi-Carmona M, Barth F, Millan J, Derocq J-M, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Breliere J-Q Le Fur G. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics 1998; 284: 644-650.
78. Rinaldi-Carmona M, Calandra B, Shire D, Bouaboula M, Oustric D, Barth F, Casellas P, Ferrara P, Le Fur G. Characterisation of two cloned human CB1 cannabinoid receptor isoforms. Journal of Pharmacology and Experimental Therapeutics 1996, 278: 871-878.
79. 3H]SR141716A, a selective brain (CB1) cannabinoid receptor. Life Sciences 1996a; 58: 1239-1247.
80. Sallan SE, Zinberg NE, Frei E. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. New England Journal of Medicine 1975; 293: 795-797.
81. Seltzman HH, Fleming DN, Thomas BF, Gilliam AF, McCallion DS, Pertwee RG, Compton DR, Manin BR. Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. Journal of Medical Chemistry 1997; 40: 3626-3634.
82. Shire D, Carillon C, Kaghad M, Calindra B, Rinaldi-Carmona M, Le-Fur G, Caput D, Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. Journal of Biological Chemistry 1995; 270: 3726-3731.
83. Skaper SD, Buriani A, Daltoso R, Petrelli L, Romanello S, Facci L, Leon A. The aliamide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proceedings of the National Academy of Sciences (USA) 1996; 93: 3984-3989.
84. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 219-227.
85. Smith PB, Martin BR. Spinal mechanisms of delta-9-tetra-hydrocannabinol-induced analgesia. Brain Research 1992; 578: 8-12.
86. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388: 773-778.
87. Sugiura TS, Kondo A, Sukagawa T, Tonegawa S, Nakane A, Yamashita Y, Ishima Y, Waku K. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. European Journal of Biochemistry 1996; 240: 53-62.
88. 2+ -dependent transacylase and phosphodiesterase activities. Biochemical and. Biophysical Research Communications 1996; 28: 113-117.
89. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ 1 opioid receptor mechanism. Science 1997; 276: 2048-2050.
90. Tashkin DP, Shapiro BJ, Frank IM. Acute effects of marihuana on airway dynamics in spontaneous and experimentally induced bronchial asthma. In: Braude M, Szara S, eds The pharmacology of marihuana. New York: Raven Press, 1976.
91. 9-tetrahydrocannabinol in mice. European Journal of Pharmacology 1994; 260: 5-13.
92. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 392-411.
93. Tsou K, Lowitz KA, Hohmann AG, Martin WJ, Hathaway CB, Bereiter DA, Walker JM. Suppression of noxious stimulusevoked expression of fos protein-like immunore activity in rat spinal-cord by a selective cannabinoid agonist. Neuroscience 1996; 70: 791-798.
94. Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylyl cyclase. Journal of Neurochemistry 1993; 61: 352-355.
95. Voth EA, Schwartz RH. Medical applications of delta-9-tetrahydrocannabinol and marijuana. American College of Physicians 1997; 126: 791-798.
96. 2 ethanolamide from anandamide by cyclooxegnase-2. Journal of Biological Chemistry 1997; 272: 21181-21186.
97. Zlas J, Stark H, Sellgman J, Levy R, Werker E, Breuer A, Mechoulam R. Early medical use of cannabis. Nature 1993; 363: 215.